Member access

4-Traders Homepage  >  Shares  >  Xetra  >  Algeta ASA    GJ9   NO0010239437

ALGETA ASA (GJ9)

0
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 

Algeta ASA : to host Capital Markets Days

11/18/2013 | 01:05am US/Eastern
Recommend:
0

Not intended for US media
  
Oslo, Norway, 18 November 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will host Capital Markets Days this week in Oslo, London and New York.  

Presentations by Algeta's Executive Management and invited guest speakers will cover topics including alpha-pharmaceutical production, a commercial update and the current life-cycle management clinical trial plan for Xofigo® (radium Ra 223 dichloride) as well as Algeta's pipeline of Targeted Thorium Conjugates.

Event summaries and guest speaker details are provided below.

Oslo, 18 November 10:00am-2:00pm (CET)
KS-Agenda Møtesenter, Haakon VII's gate 9

  • Dr Dag Clement Johannessen, Consultant Oncologist, Department of Oncology, University Hospital of Oslo, Norway 

  • Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden 

London, 19 November 10:00am-2:00pm (GMT)
Holborn Bars 2nd Floor, 138-142 Holborn

  • Dr E. David Crawford, Professor of Surgery (Urology) & Radiation Oncology, Head Urologic Oncology, University of Colorado, Denver, USA  

  • Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden 

New York, 21 November 12.30pm-4:30pm (EDT)
Parker Meridien, 118 West 57th Street

  • Dr Dan George, Director, GU Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA 

  • Dr Neal D. Shore, Director, CPI, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina, USA 

The event in New York will be webcast via www.algeta.com:
http://www.algeta.com/, where presentations will also be made available.

About Xofigo® (Radium Ra 223 Dichloride)

Xofigo is approved in Europe for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is an alpha particle-emitting pharmaceutical. Its active moiety mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent tumour cells, resulting in a potent cytotoxic effect. Additional effects on the tumour microenvironment including osteoblasts and osteoclasts also contribute to the in vivo efficacy. The alpha particle range from radium-223 is less than 100 micrometers (less than 10 cell diameters) which minimises damage to the surrounding normal tissue.

Xofigo is also approved in the US for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral disease.

In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of radium-223. Under the terms of the agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayer's sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US.

Xofigo® is a registered trademark of Bayer AG

###

For further information, please contact:

Mike Booth +1 646 410 1884
Communications & Corporate Affairs ir@algeta.com:
mailto:ir@algeta.com
Media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk:
mailto:mark.swallow@citigatedr.co.uk
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton knut.ekern@hkstrategies.com:
mailto:knut.ekern@hkstrategies.com
Investor enquiries:
Tricia Truehart +1 646 378 2953
The Trout Group ttruehart@troutgroup.com:
mailto:ttruehart@troutgroup.com

About Algeta
  
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com:
http://www.algeta.com/.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Press release:
http://hugin.info/134655/R/1743765/586642.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

HUG#1743765
Recommend :
0
React to this article
Latest news on ALGETA ASA
05/07 ALGETA ASA : Tokai Pharmaceuticals Appoints Khalid Mamlouk, Pharm.D. as Vice Pre..
05/06 Factbox - M&A frenzy transforming global pharma
05/06DJBayer to Buy Merck's Consumer Business for $14.2 Billion -- 4th Update
05/06 M&A frenzy in healthcare sector
04/28DJBayer Looks to Focus on Health Care Business --Update
04/28DJBayer Looks to Focus on Health Care Business
03/23 ALGETA ASA : UK cost agency says 'no' to Bayer prostate cancer drug Xofigo
03/19 ALGETA ASA : Delisting
03/10 ALGETA ASA : Disclosure of large shareholding
03/10 ALGETA ASA : Bayer completes voluntary takeover offer for Algeta
Advertisement
Dynamic quotes  
ON
| OFF